| Literature DB >> 31586435 |
Darius Gleiznys1, Alvydas Gleiznys1, Lina Abraškevičiūtė1, Astra Vitkauskienė2, Viktoras Šaferis3, Jurgina Sakalauskienė1.
Abstract
BACKGROUND The purpose of the present research is to analyze the effect of polyphenols and flavonoids substrat (PFS) from plants Calendula officinalis, Salvia fruticosa, Achillea millefolium, and propolis as immunomodulatory in the production of interleukin (IL)-1ß and IL-10 in peripheral blood leukocytes medium (PBLM) in patients who were diagnosed with mucositis of peri-implant tissue compared to patients with healthy implant tissue. It was hypothesized that IL-1ß and IL-10 contribute to the inflammation processes noticed in the diseases of peri-implant tissues. MATERIAL AND METHODS Sixty non-smoking patients were included in this study: patients with healthy implants (HP group) and patients with peri-implant mucositis (MP group). Peri-mucositis was diagnosed by radiologic and clinical examination. The PBLM from MP were treated with PFS at various concentrations. The levels of IL-10 and IL-1ß excreted by the PBLM stimulated and unstimulated with viable Porphyromonas gingivalis test-tube were committed by the enzyme amplified immunoassay sensitivity method. RESULTS Unstimulated and stimulated PBLM and treatment with 5.0 mg/mL or 10.0 mg/mL of PFS in the MP group produced significantly higher levels IL-10 (P<0.001) that analogous mediums of the HP group. The levels of IL-1ß decreased more considerably in the stimulated PBLM of the MP group than in those of HP group (P<0.001) after the treatment with PFS at only 10.0 mg/mL concentration. CONCLUSIONS Theses results suggest that the solution of PFS might offer a new potential for the development of a new therapeutic path to prevent and treat peri-implant mucositis.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31586435 PMCID: PMC6792512 DOI: 10.12659/MSM.915464
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Clinical data of 2 patient groups: Healthy implants (HP) group and peri-implant mucositis (MP) group.
| HP (n=30) | MP (n=30) | P | |
|---|---|---|---|
| Age (years, mean ±SD) | 63.0±1.0 | 63.1±1.1 | >0.05 |
| Probing depth (mm, mean ±SD) | 1.5±0.45 | 3.0±0.44 | <0.001 |
| Plaque index (mean ±SD) | 0 | 0.89±0.10 | <0.001 |
| Marginal bleeding (mean ±SD) | 0 | 0.79±0.11 | <0.001 |
Leukocyte count and percentage distribution in peripheral blood incubation medium.
| Groups | Leukocyte count (LC) in incubation medium (cells 1×109/L) | |||
|---|---|---|---|---|
| Differential LC | Granulocytes % | Lymphocytes % | Monocytes % | |
| HP group (n=30) | 10.1±0.12 | 43.8±6.4 | 54.5±7.8 | 2.8±1.2 |
| MP group (n=30) | 10.3±0.14 | 45.5±7.5 | 52.9±8.2 | 2.8±1.5 |
HP – patients with healthy implants; MP – patients with untreated peri-implant mucositis.
Pairwise comparisons with a Bonferroni correction, HP, IL-10.
| (I) IL10 | (J) IL-10 | Mean difference (I–J) | |
|---|---|---|---|
| IL-10 uc | IL-10 u5 | −0.0001 | 1.00 |
| IL-10 u10 | −0.0003 | 1.00 | |
| IL-10 sc | −0.0018 | 0.63 | |
| IL-10 s5 | −.0031 | 0.00 | |
| IL-10 s10 | −.0032 | 0.00 | |
| IL-10 u5 | IL-10 u10 | −0.0002 | 1.00 |
| IL-10 sc | −0.0017 | 0.64 | |
| IL-10 s5 | −.0030 | 0.01 | |
| IL-10 s10 | −.0031 | 0.02 | |
| IL-10 u10 | IL-10 sc | −0.0016 | 1.00 |
| IL-10 s5 | −.0028 | 0.01 | |
| IL-10 s10 | −.0029 | 0.00 | |
| IL-10 sc | IL-10 s5 | −0.0013 | 0.93 |
| IL-10 s10 | −0.0014 | 1.00 | |
| IL-10 s5 | IL-10 s10 | −0.0001 | 1.00 |
SD – standard deviation.
Adjustment for multiple comparisons: Bonferroni. HP – healthy patients; uc – unstimulated PBLM and control; u5 – unstimulated PBLM and 5.0 mg/mL PSF; u10 – unstimulated PBLM and 10.0 mg/mL PSF; sc – stimulated PBLM and control; s5 – stimulated PBLM and 5.0 mg/mL PSF; s10 – stimulated PBLM and 10.0 mg/mL PSF.
Pairwise comparisons with a Bonferroni correction, MP, IL-10.
| (I) IL-10 | (J) 1 β | Mean difference (I–J) | |
|---|---|---|---|
| IL-10 uc | IL-10 u5 | −0.001 | 1.000 |
| IL-10 u10 | −.013 | 0.000 | |
| IL-10 sc | −.008 | 0.000 | |
| IL-10 s5 | −.017 | 0.000 | |
| IL-10 s10 | −.043 | 0.000 | |
| IL-10 u5 | IL-10 u10 | −.012 | 0.000 |
| IL-10 sc | −.008 | 0.000 | |
| IL-10 s5 | −.016 | 0.000 | |
| IL -10 s10 | −.042 | 0.000 | |
| IL-10 u10 | IL-10 sc | .004 | 0.000 |
| IL-10 s5 | −0.004 | 0.115 | |
| IL-10 s10 | −.030 | 0.000 | |
| IL-10 sc | IL-10 s5 | −.008 | 0.000 |
| IL-10 s10 | −.035 | 0.000 | |
| IL-10 s5 | IL-10 s10 | −.027 | 0.000 |
Adjustment for multiple comparisons: Bonferroni.
MP – patients with peri-implant mucositis; IL – interleukin; uc – unstimulated PBLM and control; u5 – unstimulated PBLM and 5.0 mg/mL PSF; u10 – unstimulated PBLM and 10.0 mg/mL PSF; sc – stimulated PBLM and control; s5 – stimulated PBLM and 5.0 mg/mL PSF; s10 – stimulated PBLM and 10.0 mg/mL PSF.
Pairwise comparisons with a Bonferroni correction MP, IL-1β.
| (I) IL-1β | (J) 1β | Mean difference (I–J) | |
|---|---|---|---|
| IL-1β uc | IL-1β u5 | .004 | 0.00 |
| IL-1β u10 | .006 | 0.00 | |
| IL-1β sc | −.006 | 0.00 | |
| IL-1β s5 | 0.0006 | 1.00 | |
| IL-1β s10 | .013 | 0.00 | |
| IL-1β u5 | IL-1β u10 | .003 | 0.02 |
| IL-1β sc | −.009 | 0.00 | |
| IL-1β s5 | −0.0030 | 0.24 | |
| IL-1β s10 | .010 | 0.00 | |
| IL-1β u10 | IL-1β sc | −.012 | 0.00 |
| IL-1β s5 | −.006 | 0.00 | |
| IL-1β s10 | .007 | 0.00 | |
| IL-1β sc | IL-1β s5 | .006 | 0.00 |
| IL-1β s10 | .019 | 0.00 | |
| IL-1β s5 | IL-1β s10 | .013 | 0.00 |
Adjustment for multiple comparisons: Bonferroni.
uc – unstimulated PBLM and control; u5 – unstimulated PBLM and 5.0 mg/mL PSF; u10 – unstimulated PBLM and 10.0 mg/mL PSF; sc – stimulated PBLM and control; s5 – stimulated PBLM and 5.0 mg/mL PSF; s10 – stimulated PBLM and 10.0 mg/mL PSF.
Figure 1IL-10 levels in unstimulated and stimulated by viable Porphyromonas gingivalis leukocytes medium and treated with PFS. Significant differences at IL-10 u10, IL-10 sc, IL-10 s5 and IL-10 s10 measuring occasion. Remaining results indicate a statistically significant difference P<0.001. IL-10 – interleukin-10 (pg/mL); PFS – the polyphenols and flavonoids substrat; uc – unstimulated PBLM and control; u5 – unstimulated PBLM and 5.0 mg/mL PSF; u10 – unstimulated PBLM and 10.0 mg/mL PSF; sc – stimulated PBLM and control; s5 – stimulated PBLM and 5.0 mg/mL PSF; s10 – stimulated PBLM and 10.0 mg/mL PSF.
Figure 2IL-1β levels in unstimulated and stimulated by viable Porphyromonas gingivalis leukocytes medium and treated with PFS. Significant differences at IL-1β u5, IL-1β u10, IL-1β sc and IB-1β s10 measuring occasion. Results indicate a statistically significant difference P<0.001. IL-1β – interleukin-1β (pg/mL); PFS – the polyphenols and flavonoids substrat; PFS – the polyphenols and flavonoids substrat; uc – unstimulated PBLM and control; u5 – unstimulated PBLM and 5.0 mg/mL PSF; u10 – unstimulated PBLM and 10.0 mg/mL PSF; sc – stimulated PBLM and control; s5 – stimulated PBLM and 5.0 mg/mL PSF; s10 – stimulated PBLM and 10.0 mg/mL PSF.